T-cell Therapy Market Size, Share & Trends Analysis Report By Modality, By Therapy (CAR T-cell, Tumor-Infiltrating Lymphocytes), By Indication (Hematologic Malignancies (Lymphoma)), And Segment Forecasts, 2023 - 2030

Research Methodology

A three-pronged approach was followed for deducing the T-cell therapy market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for T-cell therapy market to gather the most reliable and current information possible.

• We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
• We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
• We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
• We pull from reliable secondary sources such as white papers and government statistics, published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
• We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of T-cell therapy market data depending on the type of information we’re trying to uncover in our research.

• Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.

• Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.

• Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.

• Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

• Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.

• Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.

• This step also entails the finalization of the report scope and data representation pattern.

• Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

T-cell Therapy Market Categorization:

The T-cell therapy market was categorized into three segments, namely therapy type (CAR T-cell Therapy, T Cell Receptor (TCR)-based, Tumor Infiltrating Lymphocytes (TIL)-based), indication (Hematologic Malignancies, Solid Tumors), and region (North America, Europe, Asia Pacific, Rest of the World).

Segment Market Methodology:

The T-cell therapy market was segmented into therapy type, indication, and region. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

• Demand estimation of each product across countries/regions summed up to from the total market.

• Variable analysis for demand forecast.

• Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.

• Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

• Used extensively for new product forecasting or analyzing penetration levels.

• Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.

• Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

• This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The T-cell therapy market was analyzed at a regional level. The globe was divided into North America, Europe, Asia Pacific, Rest of the World, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into six countries, namely, the U.S.; Canada; the UK; Germany; Japan; China.

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

T-cell therapy market companies & financials:

The T-cell therapy market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

• NOVARTIS AG - Novartis AG, a company that is publicly traded, was established as a result of a merger between Ciba-Geigy and Sandoz Laboratories. It is structured into three divisions: pharmaceuticals, Alcon, and Sandoz. The pharmaceuticals (innovative medicines) division is further split into Novartis Pharmaceuticals and Novartis Oncology. The company is involved in the provision of generics, medicines, and eye care devices. Its research and development facilities encompass the Friedrich Miescher Institute for Biomedical Research (Basel), The Genomics Institute of the Novartis Research Foundation (California), Novartis Institutes for BioMedical Research (Basel, Massachusetts, New Jersey, California, Shanghai), Novartis Institute for Tropical Diseases (Singapore), Pharmaceutical Development—East Hanover (New Jersey), and Pharmaceutical Development (Basel, Cambridge, Changshu, Hyderabad, Shanghai, Tokyo). To broaden its gene therapy portfolio, the company procured AveXis, Inc. in May 2018.

• MERCK KGAA - Merck KGaA is an international firm specializing in science and technology, with operations divided into three sectors: life sciences, healthcare, and performance materials. The life sciences sector includes Millipore Corporation (Serono SA) and Sigma-Aldrich Corporation (U.S.), which were acquired in 2010 and 2015, respectively. Through Sigma Aldrich Corporation, Merck offers a range of products and services, including organic chemical & biochemical products and assay kits. These products find extensive use in diverse areas such as research (genomics & proteomics), the creation of biotechnology & pharmaceutical molecules, and disease diagnosis. While the life sciences business has a global footprint, Merck operates under the name Millipore Sigma in the U.S. and Canada due to legal considerations. With a robust presence in regions such as Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa, Merck has a significant global reach.

• GILEAD SCIENCES, INC. - Gilead Sciences, Inc. is a biopharmaceutical firm that catalyzes the creation of novel treatments. The firm provides therapeutic solutions for diseases such as HIV, cancer, respiratory disorders, liver ailments, and cardiovascular-related conditions. Gilead has a global presence, with operations in over 30 countries. The company boasts a portfolio of 23 approved products that are commercially available, along with several therapeutic products that are currently undergoing clinical trials. In 2017, Gilead made a strategic acquisition of Kite Pharma for 12 billion USD.

• TCR2 THERAPEUTICS INC. - TCR2 Therapeutics, Inc. is a company in the clinical phase that focuses on the creation of immunotherapy treatments. The firm is at the forefront of developing T-cell therapy candidates aimed at combating cancer. Furthermore, the company has successfully developed its own T-cell therapy product, which is engineered to identify and eradicate definite cancer cells, known as TCR Fusion Construct T-cells (TRuC-T cells),

• BLUEBIRD BIO, INC. - Bluebird Bio stands as a pioneer among the handful of biotech firms spearheading the gene therapy revolution. The company's suite of product platforms enhances cancer immunotherapy, gene therapy, and gene editing. These platforms hold the promise of potentially treating or even curing a wide array of rare genetic disorders. Leveraging its comprehensive development strategies, the company is committed to creating a single-dose treatment solution devoid of complications for patients battling cancer as well as severe genetic and rare diseases.

• SORRENTO THERAPEUTICS, INC. - Sorrento Therapeutics, Inc. is a company in the clinical phase that specializes in the production of biotech products. The firm is dedicated to providing therapies that have a significant clinical impact on malignant cancers. The company is committed to producing products that can transform cancer treatment and enhance the care of cancer patients. Additionally, Sorrento is proactive in developing programs that facilitate the analysis of the application of the company’s products in the context of neurodegenerative diseases, inflammatory disorders, and autoimmune diseases.

• FATE THERAPEUTICS - Fate Therapeutics, a biopharmaceutical manufacturer in the clinical stage, is dedicated to the creation of programmed cellular immunotherapies. These therapies are tailored for patients who are battling immune disorders and cancer. The firm is also pioneering a novel cell therapy approach to generate cell therapy product candidates that can treat a wide patient population. Fate Therapeutics is engaged in the development of a variety of cell therapy product candidates, including induced pluripotent stem cells, Myeloid-derived Suppressor Cells (MDSCs), natural killer cells, and T Cells.

• PFIZER, INC. - Pfizer, Inc., a pharmaceutical corporation, produces products for a broad spectrum of areas, including diabetology, immunology, cardiology, oncology, and dermatology. Its operations are divided into two segments: Innovative Health and Essential Health. The corporation is engaged in a variety of areas: primary care, oncology, animal & consumer healthcare, and nutrition. It distributes its products in over 125 nations and operates approximately 58 manufacturing facilities globally.

• AMGEN INC. - A global biopharmaceutical firm, Amgen Inc., is engaged in the discovery, development, and commercialization of both large and small-molecule medications. The firm boasts a varied product portfolio that caters to a broad spectrum of therapeutic areas: oncology, cardiology, inflammation, nephrology, neuroscience, and bone health. Its primary competitors include Janssen Biotech, Inc.; AbbVie Inc.; Teva Pharmaceutical Industries Ltd.; Galenica Group; Roche Ltd.; Novartis; and Celgene. The company has operations in over 100 countries, with a significant footprint in the U.S. and Europe.

• CELGENE CORPORATION - Celgene Corporation, a biopharmaceutical entity, provides innovative and transformative medications. The firm is committed to the innovation, enhancement, and marketing of a variety of products created for the treatment of cancer, inflammatory & immune disorders, and other serious conditions. Celgene has partnered with Juno Therapeutics and Acceleron to develop next-generation solutions in protein homeostasis, immuno-oncology, and epigenetics for therapy development. As a result of collaborations with other firms, the company disseminates information, offers support, and provides access to therapies developed through various industry-leading programs.

Value chain-based sizing & forecasting

Supply Side Estimates

• Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.

• Segment revenue determination via variable analysis and penetration modeling.

• Competitive benchmarking to identify market leaders and their collective revenue shares.

• Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

• Identifying parent markets and ancillary markets

• Segment penetration analysis to obtain pertinent

• revenue/volume

• Heuristic forecasting with the help of subject matter experts

• Forecasting via variable analysis

T-cell Therapy Market Report Objectives:

• Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.

• Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.

• Understanding market estimates and forecasts (with the base year as 2022, historic information from 2018 to 2021, and forecast from 2023 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

T-cell Therapy Market Report Assumptions:

• The report provides market value for the base year 2022 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.

• The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.

• We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.

• All market estimates and forecasts have been validated through primary interviews with the key industry participants.

• Inflation has not been accounted for to estimate and forecast the market.

• Numbers may not add up due to rounding off.

• Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).

• Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).

• Latin America includes Central American countries and the South American continent

• Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

• Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.

• Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.

The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.